MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31.

Income Overview

Net Income
-$20,526K
EPS
-$0.25
Unit: Thousand (K) dollars

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Research and development
15,703 18,173* 15,695 14,721
General and administrative
6,630 12,580* 5,953 15,967
Total operating expenses
22,333 30,753 21,648 30,688
Operating loss
-22,333 -30,753* -21,648 -30,688
Loss on long-term investment
--1,637* -3,390
Amortization of premium on investments in u.s. treasury securities
--60 34
Other expense, net
-1 17* -9 -14
Interest expense
17 25* 22 25
Interest income
2,113 2,044* 1,456 1,268
(amortization of premium) accretion of discount on investments in u.s. treasury securities, net
42 -28* --
Total other income and expense
2,137 371* 1,365 4,585
Loss from operations before income taxes
-20,196 -30,382 -20,283 -26,103
Net loss
-20,196 -30,382 -20,283 -26,103
Net unrealized gain (loss) on investments
-330 ---
Total other comprehensive gain (loss)
-330 ---
Comprehensive loss
-20,526 ---
Basic EPS
-0.25 -0.539 -0.33 -0.6
Diluted EPS
-0.25 -0.539 -0.33 -0.6
Basic Average Shares
81,183,812 56,381,474 60,980,867 43,573,628
Diluted Average Shares
81,183,812 56,381,474 60,980,867 43,573,628
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Comprehensive loss-$20,526K Net loss-$20,196K Total othercomprehensive gain (loss)-$330K Interest income$2,113K (amortization of premium)accretion of discount on...$42K Loss from operationsbefore income taxes-$20,196K Net unrealized gain(loss) on investments-$330K Total other income andexpense$2,137K Interest expense$17K Other expense, net-$1K Operating loss-$22,333K Total operatingexpenses$22,333K Research and development$15,703K General andadministrative$6,630K

Lexeo Therapeutics, Inc. (LXEO)

Lexeo Therapeutics, Inc. (LXEO)